DK79893D0 - New vaccine - Google Patents

New vaccine

Info

Publication number
DK79893D0
DK79893D0 DK93798A DK79893A DK79893D0 DK 79893 D0 DK79893 D0 DK 79893D0 DK 93798 A DK93798 A DK 93798A DK 79893 A DK79893 A DK 79893A DK 79893 D0 DK79893 D0 DK 79893D0
Authority
DK
Denmark
Prior art keywords
tuberculosis
mycobacterium
mpt64
vaccination
polypeptide
Prior art date
Application number
DK93798A
Other languages
English (en)
Inventor
Peter Andersen
Aase Bengaard Andersen
Kaare Hasloev
Anne Lund Soerensen
Original Assignee
Statens Seruminstitut
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Statens Seruminstitut filed Critical Statens Seruminstitut
Priority to DK93798A priority Critical patent/DK79893D0/da
Publication of DK79893D0 publication Critical patent/DK79893D0/da
Priority to DE69434021T priority patent/DE69434021T2/de
Priority to EP04077505A priority patent/EP1508339A1/en
Priority to ES94919574T priority patent/ES2229220T3/es
Priority to DK94919574T priority patent/DK0706571T3/da
Priority to AT94919574T priority patent/ATE277181T1/de
Priority to PT94919574T priority patent/PT706571E/pt
Priority to NZ267984A priority patent/NZ267984A/en
Priority to PCT/DK1994/000273 priority patent/WO1995001441A1/en
Priority to CA2165949A priority patent/CA2165949C/en
Priority to EP94919574A priority patent/EP0706571B1/en
Priority to AU70688/94A priority patent/AU682879B2/en
Priority to US08/465,640 priority patent/US5955077A/en
Priority to US09/804,980 priority patent/US6991797B2/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/195—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria
    • C07K14/35—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from bacteria from Mycobacteriaceae (F)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N1/00—Microorganisms; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
    • C12N1/20—Bacteria; Culture media therefor
    • C12N1/205—Bacterial isolates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/53—DNA (RNA) vaccination
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
    • C12R2001/00—Microorganisms ; Processes using microorganisms
    • C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
    • C12R2001/185—Escherichia
    • C12R2001/19—Escherichia coli

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Wood Science & Technology (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pulmonology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Virology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Biomedical Technology (AREA)
  • Communicable Diseases (AREA)
  • General Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Mycology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK93798A 1993-07-02 1993-07-02 New vaccine DK79893D0 (da)

Priority Applications (14)

Application Number Priority Date Filing Date Title
DK93798A DK79893D0 (da) 1993-07-02 1993-07-02 New vaccine
AU70688/94A AU682879B2 (en) 1993-07-02 1994-07-01 Tuberculosis vaccine
PT94919574T PT706571E (pt) 1993-07-02 1994-07-01 Vacina contra a tuberculose
EP04077505A EP1508339A1 (en) 1993-07-02 1994-07-01 Tuberculosis vaccine
ES94919574T ES2229220T3 (es) 1993-07-02 1994-07-01 Vacuna contra la tuberculosis.
DK94919574T DK0706571T3 (da) 1993-07-02 1994-07-01 Tuberkulosevaccine
AT94919574T ATE277181T1 (de) 1993-07-02 1994-07-01 Tuberkulose-impfstoff
DE69434021T DE69434021T2 (de) 1993-07-02 1994-07-01 Tuberkulose-impfstoff
NZ267984A NZ267984A (en) 1993-07-02 1994-07-01 Tuberculosis vaccine
PCT/DK1994/000273 WO1995001441A1 (en) 1993-07-02 1994-07-01 Tuberculosis vaccine
CA2165949A CA2165949C (en) 1993-07-02 1994-07-01 Tuberculosis vaccine
EP94919574A EP0706571B1 (en) 1993-07-02 1994-07-01 Tuberculosis vaccine
US08/465,640 US5955077A (en) 1993-07-02 1995-06-05 Tuberculosis vaccine
US09/804,980 US6991797B2 (en) 1993-07-02 2001-03-13 M. tuberculosis antigens

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DK93798A DK79893D0 (da) 1993-07-02 1993-07-02 New vaccine

Publications (1)

Publication Number Publication Date
DK79893D0 true DK79893D0 (da) 1993-07-02

Family

ID=8097685

Family Applications (2)

Application Number Title Priority Date Filing Date
DK93798A DK79893D0 (da) 1993-07-02 1993-07-02 New vaccine
DK94919574T DK0706571T3 (da) 1993-07-02 1994-07-01 Tuberkulosevaccine

Family Applications After (1)

Application Number Title Priority Date Filing Date
DK94919574T DK0706571T3 (da) 1993-07-02 1994-07-01 Tuberkulosevaccine

Country Status (10)

Country Link
EP (2) EP1508339A1 (da)
AT (1) ATE277181T1 (da)
AU (1) AU682879B2 (da)
CA (1) CA2165949C (da)
DE (1) DE69434021T2 (da)
DK (2) DK79893D0 (da)
ES (1) ES2229220T3 (da)
NZ (1) NZ267984A (da)
PT (1) PT706571E (da)
WO (1) WO1995001441A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6641814B1 (en) 1997-04-02 2003-11-04 Statens Serum Institut Nucleic acids fragments and polypeptide fragments derived from M. tuberculosis
US6991797B2 (en) 1993-07-02 2006-01-31 Statens Serum Institut M. tuberculosis antigens
US7300660B2 (en) 1993-11-23 2007-11-27 The Regents Of The University Of California Abundant extracellular products and methods for their production and use
DE69435138D1 (de) 1993-11-23 2008-10-23 Univ California Reichlich vorhandene extrazelluläre produkte und methoden zu ihrer herstellung sowie ihre verwendung
US6752993B1 (en) 1993-11-23 2004-06-22 The Regents Of The University Of California Abundant extracellular product vaccines and methods for their production and use
ES2271449T3 (es) * 1995-09-01 2007-04-16 Corixa Corporation Compuestos para inmunoterapia y diagnostico de la tuberculosis.
US6290969B1 (en) 1995-09-01 2001-09-18 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
EP1712629A3 (en) * 1995-09-01 2009-09-09 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6458366B1 (en) 1995-09-01 2002-10-01 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
US6592877B1 (en) 1995-09-01 2003-07-15 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
AU765833B2 (en) * 1995-09-01 2003-10-02 Corixa Corporation Compounds and methods for immunotherapy and diagnosis of tuberculosis
RU2206574C2 (ru) * 1995-09-01 2003-06-20 Корикса Корпорейшн Полипептид, содержащий антигенный участок растворимого антигена м. tuberculosis, способ (варианты) и диагностический набор (варианты) для выявления инфекции m. tuberculosis
US6338852B1 (en) 1995-09-01 2002-01-15 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
WO1997009429A2 (en) * 1995-09-01 1997-03-13 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
GB9526178D0 (en) * 1995-12-21 1996-02-21 Taylor John Hermon Novel polynuceotides and polypeptides in pathogenic mycobacteria and their use as diagnostics,vaccines and targets for chemotherapy
US6013660A (en) * 1996-10-02 2000-01-11 The Regents Of The University Of California Externally targeted prophylactic and chemotherapeutic method and agents
AU4750597A (en) * 1996-10-11 1998-05-11 Corixa Corporation Compounds and methods for diagnosis of tuberculosis
GB9624456D0 (en) 1996-11-25 1997-01-15 Isis Innovation Assay method
US6544522B1 (en) * 1998-12-30 2003-04-08 Corixa Corporation Fusion proteins of mycobacterium tuberculosis antigens and their uses
US6982085B2 (en) 1997-04-02 2006-01-03 Statens Serum Institut TB diagnostic based on antigens from M. tuberculosis
DK1449922T3 (da) * 1997-04-02 2007-12-03 Statens Seruminstitut Nukleinsyrefragmenter og polypeptidfragmenter afledt af M. tuberculosis
US7037510B2 (en) 1997-04-18 2006-05-02 Statens Serum Institut Hybrids of M. tuberculosis antigens
AU750173B2 (en) * 1997-11-10 2002-07-11 Statens Serum Institut Nucleic acid fragments and polypeptide fragments derived from M. tuberculosis
EP1058731A2 (en) * 1998-03-06 2000-12-13 Statens Seruminstitut Production of mycobacterial polypeptides by lactic acid bacteria
GB9806093D0 (en) 1998-03-20 1998-05-20 Taylor John Hermon Diagnostics and vaccines for mycobacterial infections of animals and humans
BR9909472A (pt) * 1998-04-07 2001-09-11 Corixa Corp Polipeptìdeo purificado, processo para prevenir tuberculose, e, composição farmacêutica
ES2333073T3 (es) 1998-11-04 2010-02-16 Isis Innovation Limited Prueba diagnostica de tuberculosis.
US20020131976A1 (en) 1998-12-23 2002-09-19 Ajit Lalvani Tuberculosis vaccine
US6465633B1 (en) 1998-12-24 2002-10-15 Corixa Corporation Compositions and methods of their use in the treatment, prevention and diagnosis of tuberculosis
US6649170B1 (en) 1999-05-12 2003-11-18 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
AU4537100A (en) * 1999-05-12 2000-12-05 Statens Serum Institut Adjuvant combinations for immunization composition and vaccines
CA2376723A1 (en) * 1999-06-18 2000-12-28 James G. Ferry Compositions and methods for the prevention, treatment and detection of tuberculosis and other diseases
US7288261B2 (en) * 2000-07-10 2007-10-30 Colorado State University Research Foundation Mid-life vaccine and methods for boosting anti-mycobacterial immunity
WO2004099771A1 (en) 2003-05-08 2004-11-18 Statens Serum Institut A new specific epitope based immunological diagnosis of tuberculosis
EA012037B1 (ru) 2004-11-16 2009-06-30 Круселл Холланд Б.В. Поливалентные вакцины, содержащие рекомбинантные вирусные векторы
US8398991B2 (en) * 2005-06-22 2013-03-19 Institut Pasteur Modified ESAT-6 molecules and improved vaccine strains of Mycobacterium bovis BCG
CN100999550B (zh) * 2006-01-10 2010-10-06 中国人民解放军第三○九医院 结核分枝杆菌融合蛋白及其应用
GB0618127D0 (en) * 2006-09-14 2006-10-25 Isis Innovation Biomarker
EP2142931B1 (en) 2007-05-08 2016-06-22 Prionics AG Method for the diagnosis of tuberculosis
US20170305976A1 (en) 2014-10-23 2017-10-26 Qiagen Sciences, Llc Peptide composition and uses thereof
US10370419B2 (en) 2014-12-09 2019-08-06 The Board Of Regents Of The University Of Textas System Tuberculosis vaccine compositions and related methods
CN106248934B (zh) * 2016-08-25 2018-04-06 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌抗原蛋白Rv0446c及其T细胞表位肽的应用
CN106405107B (zh) * 2016-08-31 2018-04-06 中国疾病预防控制中心传染病预防控制所 结核分枝杆菌抗原蛋白Rv2941及其T细胞表位肽的应用
RU2631607C1 (ru) * 2016-11-22 2017-09-25 Владислав Николаевич Ласкавый Средство для профилактики лейкоза крупного рогатого скота и способ его применения

Also Published As

Publication number Publication date
ATE277181T1 (de) 2004-10-15
EP0706571A1 (en) 1996-04-17
CA2165949A1 (en) 1995-01-12
ES2229220T3 (es) 2005-04-16
EP0706571B1 (en) 2004-09-22
DK0706571T3 (da) 2005-01-31
NZ267984A (en) 1997-09-22
AU682879B2 (en) 1997-10-23
DE69434021T2 (de) 2005-09-01
PT706571E (pt) 2005-02-28
DE69434021D1 (de) 2004-10-28
WO1995001441A1 (en) 1995-01-12
AU7068894A (en) 1995-01-24
CA2165949C (en) 2011-06-07
EP1508339A1 (en) 2005-02-23

Similar Documents

Publication Publication Date Title
DK79893D0 (da) New vaccine
NO972196L (no) Polynukleotidvaksine mot tuberkulose
PT2006395E (pt) Quadro de leitura aberto de m. tuberculosis rv2660c e suas utilizações
Barnes et al. Characterization of T cell antigens associated with the cell wall protein-peptidoglycan complex of Mycobacterium tuberculosis.
EP1523331A2 (en) Therapeutic tb vaccine
CA2220063A1 (en) Acellular pertussis vaccines and methods of preparation thereof
WO2002004018A3 (en) Mid-life vaccine and methods for boosting anti-mycobacterial immunity
ATE526994T1 (de) Mtb32a antigen aus mycobakterium tuberculosis mit inaktivierter protease aktivität und fusionsproteine die das antigen enthalten
DK524289A (da) Fremgangsmaade til diagnosticering for og vaccine mod mycobakterier
Vordermeier et al. Toward the development of diagnostic assays to discriminate between Mycobacterium bovis infection and bacille Calmette-Guerin vaccination in cattle
Wu et al. Recombinant early secreted antigen target 6 protein as a skin test antigen for the specific detection of Mycobacterium tuberculosis infection
GB9409985D0 (en) Vaccine against mycobacterial infections
WO1997044463A3 (fr) Identification et clonage d'un antigene mycobacterien correspondant a une hemagglutinine de liaison a l'heparine
Larsson et al. Sensitivity to sensitins and tuberculin in Swedish children. IV. The influence of BCG-vaccination
Gilot et al. Comparative analysis of three sensitins used in cutaneous testing for tuberculosis and paratuberculosis in cattle
Austrian A brief history of pneumococcal vaccines
Hernandez-Pando et al. Recombinant BCG vaccine candidates
BAESS et al. Classification of Mycobacterium simiae by means of comparative reciprocal intradermal sensitin testing on guinea‐pigs and deoxyribonucleic acid hybridization
Maes et al. Mycobacterial infections: Are the observed enigmas and paradoxes explained by immunosuppression and immunodeficiency?
Grange Is the incidence of AIDS-associated Mycobacterium avium-intracellulare disease affected by previous exposure to BCG, M. tuberculosis or environmental mycobacteria?
Stottmeier et al. Purified protoplasmic peptides of mycobacteria: in vivo and in vitro comparison of the species specificity of purified protoplasmic peptides and purified protein derivatives of mycobacterial culture filtrates
SU1839960A1 (ru) Штамм бактерий francisella tularensis для приготовления живой вакцины против туляремийной инфекции
Singh et al. Mycobacterium phlei: A novel immunogenic strain against M. tuberculosis infection in experimental animals.
Lagrange et al. Experimental evaluation of factors conditioning the protective immunity in mycobacterial infections and related consequences for vaccination in humans.
Plouffe et al. Serological differences in Legionella pneumophila infections

Legal Events

Date Code Title Description
A0 Application filed
AHS Application shelved for other reasons than non-payment